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Abstract
Frame-disrupting mutations in the DMD gene, encoding dystrophin, compromise myofiber 
integrity and drive muscle deterioration in Duchenne muscular dystrophy (DMD). Removing one 
or more exons from the mutated transcript can produce an in-frame mRNA and a truncated but still 
functional protein. In this study, we develop and test a direct gene editing approach to induce exon 
deletion and recover dystrophin expression in the mdx mouse model of DMD. Delivery by adeno-
associated virus (AAV) of clustered regularly interspaced short palindromic repeats (CRISPR)-
Cas9 endonucleases coupled with paired guide RNAs flanking the mutated Dmd exon23 resulted 
in excision of intervening DNA and restored Dystrophin reading frame in myofibers, 
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cardiomyocytes and muscle stem cells following local or systemic delivery. AAV-Dmd CRISPR-
treatment partially recovered muscle functional deficiencies and generated a pool of endogenously 
corrected myogenic precursors in mdx mouse muscle.
Duchenne muscular dystrophy (DMD) is a progressive muscle degenerative disease caused 
by point mutations, deletions, or duplications in the DMD gene that cause genetic frame-
shift or loss of protein expression (1). Efforts under development to reverse the pathological 
consequences of DYSTROPHIN deficiency in DMD aim to restore its biological function 
through viral-mediated delivery of genes encoding shortened forms of the protein, 
upregulation of compensatory proteins, or interference with the splicing machinery to “skip” 
mutation-carrying exons in the mRNA and produce a truncated, but still functional protein 
(reviewed in (2)).
The potential efficacy of exon-skipping strategies is supported by the relatively mild disease 
course of Becker Muscular Dystrophy (BMD) patients with in-frame deletions in DMD (3, 
4), and by the capacity of antisense oligonucleotides (AONs), which mask splice donor or 
acceptor sequences of mutated exons in dystrophin mRNA, to restore biologically active 
DYSTROPHIN protein in mice (5, 6) and humans (7, 8). Yet, limitations remain for the use 
of AONs, including variable efficiencies of tissue uptake, depending on AON chemistry, a 
requirement for repeated AON injection to maintain effective skipping, and the potential for 
AON-associated toxicities ((9, 10) and Supplementary Text).
Here, we sought to address these limitations by developing a one-time, multisystemic 
approach based on the genome-editing capabilities of the CRISPR/Cas9 system. This 
system, coopted originally from Streptococcus pyogenes (Sp), couples a DNA double strand 
endonuclease with short “guide RNAs” (gRNAs) that provide target specificity to any site in 
the genome that also contains an adjacent `NGG' protospacer adjacent motif (PAM) (11–14), 
thereby enabling targeted gene disruption, replacement, and modification.
To apply CRISPR/Cas9 for exon deletion in DMD, we first established a reporter system for 
CRISPR activity by “repurposing” the existing Ai9 mouse reporter allele, which encodes the 
fluorescent tdTomato protein downstream of a ubiquitous CAGGS promoter and “floxed” 
STOP cassette (15, 16) (Fig. S1A). Exposure to SpCas9, together with paired gRNAs 
targeting near the Ai9 loxP sites (hereafter Ai9 gRNAs), resulted in excision of intervening 
DNA and expression of tdTomato (Fig. S1A,B,E). We next designed and tested paired 
gRNAs (hereafter Dmd23 gRNAs, Fig. S1C) directed 5' and 3' of mouse Dmd exon23, 
which in mdx mice carries a nonsense mutation that destabilizes Dmd mRNA and disrupts 
DYSTROPHIN expression (17). Finally, we coupled the paired Dmd23 and Ai9 gRNAs 
using a two plasmid system that links expression of the CRISPR activity reporter (tdTomato) 
to genome editing events at the Dmd locus (Fig. S1D). In vitro transfection of primary 
satellite cells from mdx mice carrying the Ai9 allele (hereafter mdx;Ai9 mice) with SpCas9 
+ Ai9-Dmd23 coupled gRNAs induced gene editing at both the Ai9 locus, demonstrated by 
tdTomato expression (Fig. S1E), and Dmd locus, detected by genomic PCR (Fig. 1A) and 
confirmed by amplicon sequencing (Fig. S1F). Dmd editing was not detected in mdx;Ai9 
cells receiving Ai9 gRNAs alone (Fig. 1A), although tdTomato expression was equivalently 
induced (Fig. S1E).
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To confirm that CRISPR-mediated Dmd editing results in irreversible genomic modification 
and production of exon-deleted mRNA and protein, primary satellite cells from mdx;Ai9 
mice were co-transfected with SpCas9 + Ai9 or Ai9-Dmd23 gRNAs, FACSorted based on 
tdTomato expression, expanded in vitro (18), and differentiated to myotubes. RT-PCR (Fig. 
1B) and amplicon sequencing (Fig. S1G) from these myotubes detected exon23-deleted 
Dmd mRNA in cells receiving Ai9-Dmd23 coupled gRNAs, but not in cells receiving only 
Ai9 gRNAs. Taqman analysis (9) further indicated that exon23-deleted transcripts 
represented 24–47% of total Dmd mRNA in cells receiving Ai9-Dmd23 coupled gRNAs, 
whereas exon23 deletion was undetectable with Ai9 gRNAs alone (Fig. S1H). 
DYSTROPHIN protein expression was also restored in CRISPR-modified mdx;Ai9 cells, as 
detected by Western blot of in vitro differentiated myotubes (Fig. 1C) and immunostaining 
of muscle sections from mdx mice transplanted with gene-edited mdx;Ai9 satellite cells 
(Fig. 1D and S1I). These data demonstrate that CRISPR/Cas9 can direct sequence-specific 
modification of disease alleles in primary muscle stem cells that retain muscle engraftment 
capacity.
We next adapted CRISPR for delivery via adeno-associated virus (AAV), employing the 
smaller Cas9 ortholog from Staphylococcus aureus (SaCas9), which can be packaged in 
AAV and programmed to target any locus in the genome containing a “NNGRR” PAM 
sequence (19). We generated Sa gRNAs targeting Ai9 and introduced several base 
modifications into the gRNA scaffold to enhance gene targeting by SaCas9 (Fig S2A–C). 
Using this modified scaffold, we tested Dmd23 Sa gRNAs (Fig. S2D) and produced AAVs 
encoding SaCas9 and Ai9 Sa gRNAs or Dmd23 Sa gRNAs in a dual (Fig. S3A) or single 
(Fig. S3B) vector system. Comparison of exon23 excision efficiencies in transduced mdx 
myotubes demonstrated more efficient excision by dual AAV-CRISPR (Fig. S3C,D), as 
compared to single vector AAVs. Therefore, to test the potential for in vivoDmd targeting by 
CRISPR/Cas9, we pseudotyped dual AAVs (AAV-SaCas9 + AAV-Ai9 gRNAs; hereafter, 
AAV-Ai9 CRISPR) to serotype 9, which exhibits robust transduction of mouse skeletal and 
cardiac muscle (20), and injected these AAVs into the tibialis anterior (TA) muscles of 
mdx;Ai9 mice (7.5E+11 vg each). Four weeks later, muscles were harvested to assess 
genome-editing events. TdTomato fluorescence was detected in muscles injected with AAV-
Ai9 CRISPR, but not in muscles injected with vehicle alone (Fig. S4A). Co-delivery of 
AAV9-SaCas9 + AAV9-Dmd23 gRNAs (hereafter AAV-Dmd CRISPR) likewise yielded 
robust and specific modification of the Dmd locus in TA muscles in vivo. Genomic PCR 
(Fig. 2A) and Sanger sequencing (Fig. S4B) demonstrated exon23 excision in muscles 
injected with AAV-Dmd CRISPR, but not AAV-Ai9 CRISPR. Next-generation sequencing 
indicated minimal activity at the predicted highest-ranking genomic off-target sites (Fig. 
S12). RT-PCR (Fig. 2B) and sequencing (Fig. S4C) further confirmed the presence of 
exon23-deleted Dmd mRNA in muscles receiving AAV-Dmd CRISPR, with an average 
exon23-excision rate of 39%±1.8% (Fig. S3E). In vivo CRISPR-mediated targeting of Dmd 
exon23 restored DYSTROPHIN expression in skeletal muscle, as detected by Western blot 
(Fig. 2C), immunofluorescence (Fig. 2D) and capillary immunoassay (Fig. S5A). Other 
pathological hallmarks of dystrophy were also restored in AAV-Dmd CRISPR injected 
muscles, including sarcolemmal localization of the multimeric dystrophin-glycoprotein 
complex and neuronal nitric-oxide synthase (Figs. S6 and S7). In contrast, DYSTROPHIN 
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expression was undetectable by Western (Fig. 2C) and present only on rare revertant fibers 
in mdx;Ai9 mice receiving control AAV-Ai9 CRISPR (Fig. 2D; (21)). Finally, to evaluate 
the functional consequences of CRISPR-mediated induction of exon23-deleted 
DYSTROPHIN, we subjected a subset of mdx;Ai9 mice injected intramuscularly with AAV-
Dmd CRISPR to in situ muscle force assessment. Muscles receiving AAV-Dmd CRISPR 
showed significantly increased specific force (Fig. 2E) and attenuated force drop after 
eccentric damage (Fig. 2F), as compared to contralateral, vehicle-injected muscles and also 
AAV-Ai9 CRISPR injected muscles. In contrast, differences in specific force (Fig. 2E) and 
force drop (Fig. 2F) for AAV-Ai9 CRISPR injected mice were not significantly different 
between the virus-injected and vehicle-injected muscles.
We next evaluated the potential for multisystemic gene editing in vivo using AAV-CRISPR. 
Dual AAV-Ai9 CRISPR vectors (1.5E+12 vg each) were co-injected intraperitoneally into 
mdx;Ai9 mice at postnatal day 3 (P3). Three weeks later, widespread tdTomato expression 
was detected in all cardiac and skeletal muscles analyzed (Fig. S8A). Parallel injections of 
mdx;Ai9 mice with AAV-Dmd CRISPR revealed exon23-deleted transcripts in multiple 
skeletal muscles and cardiac muscle, with targeting levels varying from 3–18% in different 
muscle groups (Fig. 3A and S3F). Exon23 was not excised in animals receiving AAV-Ai9 
CRISPR instead (Fig. 3A, S3F and S8B). Finally, Western blot (Fig. 3B and S8C), 
immunofluorescence (Fig. 3C), and capillary immunoassay (Fig. S5B) confirmed that 
DYSTROPHIN protein was largely absent in muscles of control mdx;Ai9 mice receiving 
AAV-Ai9 CRISPR and restored in mice receiving AAV-Dmd CRISPR. Similar systemic 
dissemination of AAV and excision of exon23 in multiple organs were seen in two adult 
mice injected intravenously with AAV-Dmd CRISPR at 6 weeks of age (Fig. S9).
Dystrophic pathology and other muscle injuries activate muscle stem cells (also known as 
satellite cells), leading to regenerative responses that add new nuclei to damaged fibers ((2) 
and see Supplementary Text). To evaluate AAV-CRISPR gene editing in satellite cells in 
vivo, we crossed mdx;Ai9 mice with Pax7-ZsGreen animals, in which satellite cells are 
specifically marked by green fluorescence (22), and injected these animals intramuscularly 
or systemically with AAV9 encoding Cre (hereafter, AAV-Cre) or Ai9-CRISPR components. 
Muscles were harvested 2 weeks later (Fig. 4A), and analyzed by FACS. tdTomato 
expression was apparent in Pax7-ZsGreen+ satellite cells following local or systemic 
delivery of AAV-Cre or AAV-Ai9 CRISPR (Fig. 4B and S10A–C), although excision rates 
were lower for AAV-Ai9 CRISPR than for AAV-Cre. In vitro differentiation of ZsGreen+ 
satellite cells from mice receiving intramuscular or systemic AAV-Cre or AAV-Ai9 CRISPR 
produced tdTomato+ myotubes, demonstrating preservation of myogenic potential in AAV-
transduced and gene-edited satellite cells (Fig. 4C and S10D). TdTomato+ gene–edited 
satellite cells also engrafted recipient mdx muscle and contributed to in vivo muscle 
regeneration after transplantation (Fig. S10E).
We next analyzed Dmd editing in Pax7-ZsGreen+ satellite cells following intramuscular or 
systemic delivery of AAV-Dmd CRISPR or AAV-Ai9 CRISPR. Satellite cells were isolated 
by FACS, expanded and differentiated in vitro (Fig. 4A). RT-PCR revealed a truncated Dmd 
transcript of the expected size and sequence for gene-edited Dmd in satellite cell-derived 
myotubes from many of the AAV-Dmd CRISPR injected muscles, but none of the AAV-Ai9 
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CRISPR injected muscles (Fig. 4D and S10F,H,I). Quantification of exon23-excision 
revealed variable efficiencies (Fig. S10G,J), likely reflecting targeting of only a subset of 
endogenous satellite cells that may be variably represented among the isolated and cultured 
cells. Finally, genomic PCR and amplicon sequencing confirmed targeted excision at the 
Dmd locus in satellite cell-derived myotubes (Fig. S10K), and capillary immunoassay 
analysis revealed restored DYSTROPHIN expression (Fig. S10L). As expected, injection of 
AAV-Dmd CRISPR did not induce tdTomato expression in satellite cells or myofibers of 
mdx;Ai9 mice (Fig. S11).
In summary, this study provides proof-of-concept evidence supporting the efficacy of in vivo 
genome editing to correct disruptive mutations in DMD in a relevant dystrophic mouse 
model. We show that programmable CRISPR complexes can be delivered locally and 
systemically to terminally differentiated skeletal muscle fibers and cardiomyocytes, as well 
as muscle satellite cells, in neonatal and adult mice, where they mediate targeted gene 
modification, restore DYSTROPHIN expression and partially recover functional deficiencies 
of dystrophic muscle. As prior studies in mice and humans indicate that DYSTROPHIN 
levels as low as 3–15% of wild-type are sufficient to ameliorate pathologic symptoms in the 
heart and skeletal muscle (23–26), and levels as low as 30% can suppress the dystrophic 
phenotype altogether (27) and protect dystrophic muscle from damage (28), the restoration 
of DYSTROPHIN achieved here by one-time administration of AAV-Dmd CRISPR clearly 
encourages further evaluation and optimization of this system as a new candidate modality 
for the treatment of DMD (see Supplementary Text).
 Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. DYSTROPHIN expression in CRISPR-modified dystrophic satellite cells
(A) Detection of exon23 excision by genomic PCR in myotubes derived from satellite cells 
transfected with SpCas9 and Ai9 gRNAs (left lanes) or coupled Ai9-Dmd23 gRNAs (right 
lanes). Unedited genomic product, 1572bp; gene-edited product (red asterisk), 1189bp. M, 
molecular weight marker. (B) RT-PCR detection of exon23-deleted mRNA. Unedited RT-
PCR product: 738bp; exon23-deleted product (blue asterisk): 525bp. (C) Western blot 
detecting DYSTROPHIN in myotubes derived from gene-edited satellite cells. A.U.: 
Arbitrary Unit, normalized to GAPDH (loading control). DYS: DYSTROPHIN, WT: wild 
type (D) DYSTROPHIN immunofluorescence in mdx muscles transplanted with satellite 
cells transfected ex vivo with SpCas9 + Ai9 gRNAs (top) or SpCas9 + Ai9-Dmd23 coupled 
gRNAs (bottom). For merge: Green: DYSTROPHIN; Red: tdTomato; Blue: DAPI (nuclei). 
Scale bar: 200 μm. See also Fig. S1I.
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Figure 2. AAV-CRISPR enables in vivo excision of Dmd exon23 and restores DYSTROPHIN 
expression in adult dystrophic muscle
(A,B) Detection of exon23 excision in TA muscles from mdx;Ai9 mice injected 
intramuscularly with AAV-Ai9 CRISPR (left lanes) or AAV-Dmd CRISPR (right lanes) by 
genomic PCR (A; unedited product 1012bp; exon-excised product 470bp) and RT-PCR (B). 
Asterisks mark gene-edited bands. M, molecular weight marker. (C) Western blot detecting 
DYSTROPHIN in muscles injected with AAV-Ai9 CRISPR (left) or AAV-Dmd CRISPR 
(right), with relative signal intensity determined by densitometry at bottom. A.U.: Arbitrary 
Unit, normalized to GAPDH. (D) Representative immunofluorescence images for 
DYSTROPHIN (green) and DAPI (blue) in mdx;Ai9 muscles injected with AAV-Ai9 (left) 
or AAV-Dmd (right) CRISPR. Scale bar: 500 μm. (E,F) Muscle specific force (E) and 
decrease in force after eccentric damage (F) for wild type mice injected with vehicle (n=9), 
mdx;Ai9 mice injected with AAV-Dmd CRISPR in the right TA and vehicle in the left TA 
(n=12), mdx;Ai9 mice injected with AAV-Ai9 CRISPR in the right TA and vehicle in the left 
TA (n=12). *P<0.05, **P<0.01, n.s., not significant, One-Way ANOVA with Newman-Keuls 
multiple comparisons test.
Tabebordbar et al. Page 8





















Figure 3. Systemic dissemination of AAV-CRISPR targets Dmd exon23 and restores 
DYSTROPHIN in dystrophic cardiac and skeletal muscles
(A) Exon23-deleted transcripts in muscles quantified by Taqman. Data plotted for individual 
mice (n=7 receiving AAV-Dmd CRISPR (blue) and n=3 receiving AAV-Ai9 CRISPR (red)) 
and overlaid with mean ± SEM. (B) Western blots detecting DYSTROPHIN in the indicated 
muscles of mdx;Ai9 mice receiving systemic AAV-CRISPR. Right lanes correspond to 
muscles from 7 different mice injected intraperitoneally with AAV-Dmd CRISPR. Relative 
signal intensity, determined by densitometry, presented as A.U.: Arbitrary Unit normalized 
to GAPDH. (C) Representative immunofluorescence staining for DYSTROPHIN (green) in 
mdx;Ai9 mice injected with AAV-Ai9 (top) or AAV-Dmd (bottom) CRISPR. Blue: DAPI 
(nuclei). Scale bar: 200 μm.
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Figure 4. Satellite cells in dystrophic muscles are transduced and targeted with systemically 
disseminated AAV-CRISPR
(A) Experimental design. (B) Percent of ZsGreen+ satellite cells expressing tdTomato+ after 
intraperitoneal injection of Pax7-ZsGreen+/−;mdx;Ai9 mice. Individual data points overlaid 
with mean ± SD; vehicle (n=3), AAV-Cre (n=4) AAV Ai9 CRISPR (n=5). (C) 
Representative immunofluorescence of myotubes differentiated from FACSorted satellite 
cells from mice injected intraperitoneally with vehicle, AAV-Cre, or AAV-Ai9 CRISPR. 
Green: Myosin heavy chain (MHC); Red: tdTomato. Blue: DAPI (nuclei) Scale bar: 200 μm. 
(D) Exon23-deleted DMD mRNA in satellite-cell derived myotubes from mice previously 
injected intraperitoneally with AAV-Dmd CRISPR (right lanes), compared to control AAV-
Ai9 CRISPR (left lanes).
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